CONTINUE TO SITE
OR WAIT 15 SECS
South Korea-based Mezzion Pharma Co., a leader in rare disease therapeutics, has announced the expansion of it
Singapore-based biopharmaceutical company Specialised Therapeutics (ST) has expanded its existing su
The Public Health Systems Research Institute (PHRI) and Novo Nordisk Pharma (Thailand) Co. have sign
A research team led by Dr Der-Yang Cho, Superintendent of China Medical University Hospital (Taiwan), in colla
RevolKa Ltd., a venture-backed biotech company providing a cutting-edge artificial intelligence (AI)-driven pr
Administered through the National Health and Medical Research Council’s (NHMRC) Clinical Trials and
Gene Solutions has formalised a strategic collaboration with Zhejiang Shaoxing Topgen Biomedica
Indian startup GenepoweRx, a trailblazer in artificial intelligence (AI)-powered personalised medicine ba
Cytiva, a Danaher company and global life sciences leader, has completed significant expansion projects in sev
WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has ki
APAC'S ALLIANCE-DRIVEN BIOTECH BOOM
Partnerships are a cornerstone of the biotech innovation process. COVID-19 acted as a catalyst, accelerating collaboration across the sector and prompting partnerships between established players for the first time. Since then, biotech alliances have become more diverse, frequent, and strategically important, especially in the Asia-Pacific (APAC) region. Biotech partnerships of APAC differ in a variety of ways from most global collaborations, primarily due to the unique geopolitical and socio-economic landscape of the region. The region has innovation hubs like Japan and South Korea as well as large, high-growth markets such as China and India. As China rapidly scales its biopharma capabilities, it is becoming both a key market and an innovator. This transformation has redefined regional deal-making, shifting the focus from technology transfer to co-development, shared commercialisation, and strategic alignment. APAC biotech deals are no longer early-stage R&D plays, they are beginning to span the full lifecycle, from bench to bedside, including commercialisation milestones. Let’s explore further the APAC's wave of regional biotech partnerships during the first five months of this calendar year ie. from January to May 2025.
DIA 2024 Global Annual Meeting 2025
DIA
meetings@nasaglobe.org https://www.diaglobal.org/en/conference-listing/annual-meetingsWashington, DC
Launch/Peptide Formulation G Delivery Summit
Hanson Wade
info@hansonwade.com https://next-gen-peptide-formulation.com/Boston
